ABSTRACT BACKGROUND
THIMEROSAL (merthiolate) is an antiseptic and disinfectant that has been used for decades as a preservative in various consumer and medical products, such as cosmetics, ophthalmologic medications, contact lens solutions, immunoglobulin preparations, and vaccines. Thimerosal is a condensation product of thiosalicylic acid and of ethylmercuric chloride, an organic mercurial compound. It is also a notoriously frequent contact allergen; the initial report of allergic reactions to thimerosal dates back to 1942. 1 The clinical relevance of thimerosal sensitivity has been debated over the past decade, as has the rationale for including this substance in the standard patch test series., 2-5 In fact, thimerosal recently was voted off the North American Contact Dermatitis Group standard patch test series. It is nevertheless still present on the Japanese Society for Contact Dermatitis standard patch test series and is one of the 23 allergens found on T.R.U.E. TEST panels (Kabi Pharmacia Service A/S, Hillerød, Denmark)., 5 Reported sensitization rates vary from 1 to 37% and are generally high in countries with mandatory immunization programs, as well as in countries where thimerosal is widely used as an over-the-counter topical disinfectant., 6-8
In 2001, Suneja and Belsito published the results of 5 years of systematic patch testing with thimerosal in Kansas City, KS.9 Fifty patients (8.7% of their total population) were allergic to this allergen, and this group consisted predominantly of women. Secretaries, health care workers, and cooks were sensitized more often, and concomitant reactions to tixocortol pivalate, neomycin, and bacitracin were most frequently observed. However, very few positive reactions to thimerosal were found to be relevant. The objective of our study is to report the prevalence of sensitivity to thimerosal during 11 years of patch testing in a Canadian center, to correlate positive findings with patients' demographic data, to assess the clinical significance of positive results of patch tests for thimerosal, and to compare our findings with those of Suneja and Belsito.
Patients and Methods
Between July 1991 and June 2002, 3,584 patients were patch-tested in the contact dermatitis clinic of the Royal Victoria Hospital, Montreal, Canada. The allergens were obtained from Chemotechnique Diagnostics AB, Malmö, Sweden, and were applied on Finn Chambers (Epitest Ltd Oy, Tuusula, Finland) on Scanpor tape (Alpharma AS, Vennesla, Norway). Patch testing was performed according to the standard procedure; readings were done 48 hours (d2) and 96 hours (d4) after the initial application. At the last visit, the relevance of each positive reaction was categorized as unknown, possible or definite, and past or present. From July 1991 until the end of December 1998, our routine screening tool was the European Standard series, supplemented with additional series when clinically indicated. During that period, 2,175 patients were tested; of those 843 patients were tested with thimerosal (0.1% in petrolatum) on the basis of a history of potential allergy to cosmetics or of occupational exposure to disinfectants. Between January 1999 and June 2002, 1,409 patients were assessed and were routinely tested for reaction to thimerosal with the North American Standard series or the North American Contact Dermatitis Group Standard series. Thus, of 3,584 patients seen in the contact dermatitis clinic over the 11-year period, 2,252 were tested for reaction to thimerosal.
Collected data on occupations and concomitant reactions in the thimerosal-positive and control populations were statistically analyzed with the Fisher exact test.
Results
Positive reactions to thimerosal were observed in 102 (4.53%) of the 2,252 subjects tested over the 11-year period. Of the 843 recipients of aimed patch testing, 37 (4.39%) had positive reactions to thimerosal whereas in the group of 1,409 patients who were systematically tested to thimerosal, 65 (4.61%) had positive reactions. This difference was not statistically significant (p = .8864). The demographic and clinical characteristics of the thimerosal-positive patients are shown in Table 1 . The mean age of thimerosal-positive patients was 42 years, and distribution by age groups followed a bell-shaped curve that paralleled that of all the patients tested in the study period. A strong female predominance was noted (p = .06812), as 77 (75.5%) of the 102 thimerosalpositive patients were women. Women, however, represented the majority of the tested population (ie, 66.7%). A personal atopic diathesis, defined as current or past history of flexural eczema, asthma, or allergic rhinitis, was present in 40 (39.2%) of the thimerosal-positive patients whereas 38 (37.2%) had a positive family history. http://journals.bcdecker.com/showTextPrint.aspx?showType=fullText&…14,%202003/issue%2003,%20September/ajd_2003_6152/ajd_2003_6152.xml Of the 3,482 patients who had negative results or who were not tested with thimerosal, 1,292 (37.1%) suffered from atopy and 1,102 (31.6%) reported a positive family history.
The sites of involvement differed between the 37 thimerosal-allergic patients tested before January 1999 and the 65 patients who had positive reactions after that date (see Table 1 ). Patients in the former group showed predominant involvement of the face (15 patients, or 40%) and eyelids (11 patients, or 30%); the hands were affected in 10 (27%) of the cases. Of the 65 patients who had positive reactions after December 1998, 24 patients (37%) had lesions on the hands, 14 (21.5%) had facial involvement, and 10 (15.4%) had dermatitis localized exclusively to the eyelids. By comparison, of the remaining 3,482 patients, 1,105 (31.7%) had lesions on the hands, 732 (21%) presented with facial dermatitis, and 483 (13.9%) displayed palpebral lesions.
Among thimerosal-positive patients, 31 (30.4%) were office workers, 9 (8.8%) were homemakers, 9 (8.8%) were students, and 5 (4.9%) were retired ( Table 2 ). This distribution paralleled that seen in the remainder of the tested population, in which 810 subjects (23.2%) held office jobs, 578 (16.6%) were homemakers, 215 (6.2%) were students, and 216 (6.2%) were retired. However, with 12 (11.8%) medical doctors, nurses, or physiotherapists and 7 (6.9%) dentists or dental assistants, the thimerosal-positive group differed from the thimerosal-negative or untested cohort, which was composed of 139 (4%) and 48 (1.4%) professionals of these two respective groups. In addition, laboratory technicians and chemists were overrepresented in the thimerosal-positive group (8 patients [7. 8%] vs 73 patients [2.1%] in the other group). These differences reached statistical significance (see Table 2 ).
Seventy-two patients (70.5%) who reacted to thimerosal also had positive reactions to other allergens ( Table  3) . Twenty-six (70.3%) of the 37 patients tested prior to January 1999 had more than one positive patch-test result, as compared with 46 (71%) of the 65 patients later tested. Patients with multiple sensitizations reacted to an average of 2.5 allergens (range, 2 to 9). Thimerosal-positive patients were more likely to react to metallic mercury, tixocortol pivalate, phenylmercuric acetate, nickel, colophony, bacitracin, cobalt, and fragrance mix. For these allergens, the difference between the thimerosal-positive and control populations was statistically significant.
Only 8 (7.8%) of the 102 positive reactions to thimerosal were felt to be relevant. In no case was it possible to establish a definite relevance, either because the presence of thimerosal could not be verified in the patient's products or because patch testing with these products gave negative results. Of the 37 thimerosal-positive patients tested prior to January 1999, 5 (13.5%) had reactions that were possibly relevant. Of the 1,409 patients who were later routinely tested for reaction to thimerosal, 65 had positive reactions, but only 3 (4.6%) of these reactions were rated as possibly relevant.
Discussion
Sensitization to thimerosal has been reported with varying frequency worldwide. Most reactions are local and mild, involving sites of applications of tincture of merthiolate10 or involving blepharoconjunctivitis from ocular preparations., 11 Few cases of systemic contact dermatitis have been described,, 12 and one case of lifethreatening laryngeal edema in a patient treated for sore throat with a thimerosal-containing antiseptic spray has been reported., 13 The major source of sensitization has been postulated to result from previous vaccinations, when thimerosal was used as a preservative., 2,14,15 It is important, however, that patch-test positivity to thimerosal has been shown not to be a contraindication to intramuscular injection with thimerosalcontaining vaccines., 16
Our study sheds additional light on the prevalence of thimerosal sensitization in a North American population and on the difficulty of establishing the relevance of such reactions. Although some fluctuations were observed over the years, the average rate of thimerosal sensitization was 4.53% of the total patient population tested in our contact dermatitis clinic. This makes thimerosal the fifth most common allergen in our practice. In comparison, Suneja and Belsito found a higher sensitization rate of 8.7%, which placed thimerosal in sixth position in their study.9 Our study population can be divided into two subgroups: those who underwent aimed patch testing before January 1999 and those who were routinely tested with thimerosal after December 1998. There was no difference in the detection of positive reactions, and the sensitization rate was 4.39% in the http://journals.bcdecker.com/showTextPrint.aspx?showType=fullText&…14,%202003/issue%2003,%20September/ajd_2003_6152/ajd_2003_6152.xml There was no difference in the detection of positive reactions, and the sensitization rate was 4.39% in the former group and 4.61% in the latter. Thus, the sensitization rate appears relatively constant over the 11 years of the study, and importantly, has not been affected by the inclusion of thimerosal in our standard patch-testing series after December 1998.
The age distribution of our thimerosal-positive patients paralleled that of the control population. This is in contrast to earlier publications that found sensitization to be more prevalent in the third decade of life.7,17-21 Our findings are consistent with those of Cox and Forsyth and with those of Suneja and Belsito., 6,9 Also in accordance with these authors, we found no difference in the prevalence of atopy between our thimerosalpositive and control populations. In the study by Suneja and Belsito, a strong female predominance in the thimerosal-positive patients was observed; 74% were women, as compared to 60% in their control population., 9 Similarly, in our study, 75.5% of thimerosal-positive patients were women, compared to 66.7% of the control population. It is believed that the use of cosmetics and an increased rate of vaccination in the female population account for these observed trends., 9
We found no difference in the sites of involvement between the control population and the thimerosal-positive patients tested after January 1999. However, patients tested prior to 1999 had predominant involvement of the face and eyelids. At that time, thimerosal was included in our preservatives and cosmetics series, and patients tested had a higher pretest probability of developing contact dermatitis from cosmetics or ocular preparations. There was an increased incidence of thimerosal sensitization in chemists and laboratory technicians, as well as in health care workers, including medical doctors, registered nurses, dentists, and dental assistants. These individuals are often women, and they may have been occupationally exposed to disinfectants, thimerosalcontaining medications, or metallic mercury (eg, amalgam). In addition, this population is considered to be at a higher risk for influenza and hepatitis A and B and is therefore immunized against these diseases at a much higher rate than is the general population. This may explain the increased frequency of positivity to thimerosal in this group, a conclusion also reached by Suneja and Belsito.9 Similarly, we also found a trend toward an increased incidence of thimerosal reactions in homemakers and office workers, most of whom were women.
Among our thimerosal-positive patients, we found a higher prevalence of sensitization to nickel, cobalt, and fragrance mix, which may be explained by the female predominance in this group. We also found a higher prevalence of sensitization to colophony that cannot be readily explained. Noteworthy is the increased prevalence of allergy to phenylmercuric acetate and to metallic mercury. Even though ethylmercuric chloride is the predominant antigenic determinant in thimerosal,22 various authors have found a low level of crossreactions between thimerosal and other mercurials., 1,2,23 Because of this, thimerosal is not a reliable marker of sensitivity to mercury. However, other authors have reported a high rate of cross-reactions between thimerosal and inorganic or organic mercurials and metallic mercury., 6 Therefore, we have reason to wonder if some of our positive reactions to thimerosal might not represent cross-reactions in patients primarily sensitized by dental amalgam or by phenylmercuric acetate in cosmetics.
In agreement with Suneja and Belsito, we observed an increased prevalence of positive reactions to tixocortol pivalate and bacitracin in our thimerosal-positive patients. Tixocortol pivalate is a marker for sensitization to hydrocortisone,24 and bacitracin is present in numerous topical antibiotic preparations for cutaneous, otic, and ophthalmic use. Such products often contain thimerosal,, 25 and their use may have led to the development of multiple sensitizations, including sensitization to thimerosal. Alternately, these preparations may have been used to treat a preexisting thimerosal allergy, causing subsequent sensitization to the corticosteroid or antibiotic. However, contrary to Cox and Forsyth, 6 and to Suneja and Belsito,, 9 we did not find a higher prevalence of positive reactions to neomycin in our thimerosal-positive population than in the control group.
In none of the cases in our study was it possible to definitely establish the relevance of positive reactions to thimerosal. Reactions were deemed possibly relevant in eight cases only. All cases involved the face or eyelids, and all but two patients had reactions to other mercurials. One patient had facial lesions within hours of receiving dental amalgam fillings and had positive reactions to metallic mercury. Another had oral lesions adjacent to amalgam fillings and was also allergic to metallic mercury. A dentist with widespread dermatitis was sensitized to metallic mercury, carba mix, and propylene glycol. Three women with eyelid dermatitis reacted to phenylmercuric acetate. In these cases, positive reactions to thimerosal may represent cross-http://journals.bcdecker.com/showTextPrint.aspx?showType=fullText&…14,%202003/issue%2003,%20September/ajd_2003_6152/ajd_2003_6152.xml reacted to phenylmercuric acetate. In these cases, positive reactions to thimerosal may represent crossreactions and not necessarily primary sensitization. One man with recurrent episodes of severe blepharoconjunctivitis had used many ocular lubricants, corticosteroids, and antibiotic eye drops. In addition to thimerosal, he reacted to neomycin, bacitracin, polymyxin B, budesonide, carba mix, and thiuram mix. His condition improved with avoidance of allergens, but the precise role of thimerosal in his condition could never be ascertained. The only case with a probable relevance involved a woman who developed facial lesions soon after she began using a contact lens cleaning solution containing thimerosal. She had no concomitant reactions, and her lesions cleared when she switched to a thimerosal-free product. Although the fluid was likely responsible for her dermatitis, sensitization could still have occurred from other sources, years earlier.
In conclusion, our findings are generally in agreement with those of recent studies. Thimerosal remains an extremely common sensitizer despite its declining use in cosmetics, in ocular preparations, and as a skin disinfectant. Vaccination appears to be mostly responsible for those positive reactions. Fortunately, thimerosal allergy does not represent a contraindication for vaccination. Relevant reactions to thimerosal are rarely encountered, and this compound should be removed from standard patch-testing series. 
